Cargando…
Efficacy and safety of Lianhua Qingwen in the treatment of patients with moderate COVID-19 infection: A protocol for systematic review and meta analysis
BACKGROUND: : As of June 2020, more than 7 million cases of coronavirus disease (COVID-2019) have been reported worldwide. At present, there is no vaccine or antiviral for the novel coronavirus pneumonia. Lianhua Qingwen (LQ), a Chinese medicine formula, has been authorized by the Chinese government...
Autores principales: | Liu, Nanyang, Zhang, Tingting, Ma, Lina, Wang, Huican, Cao, Yu, Yang, Yang, Pei, Hui, Li, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437850/ https://www.ncbi.nlm.nih.gov/pubmed/32872017 http://dx.doi.org/10.1097/MD.0000000000021614 |
Ejemplares similares
-
Association between ABO blood groups and risk of coronavirus disease 2019: A protocol for systematic review and meta-analysis
por: Liu, Nanyang, et al.
Publicado: (2020) -
Efficacy and Safety of Chinese Medicine Lianhua Qingwen for Treating COVID-19: An Updated meta-Analysis
por: Li, Yapeng, et al.
Publicado: (2022) -
Efficacy and Safety of Lianhua Qingwen for Patients with COVID-19: A Systematic Review and Meta-Analysis
por: Sun, Xiao-hu, et al.
Publicado: (2022) -
The efficacy and safety of Lianhua Qingwen (LHQW) for coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis
por: Zhang, Qiongshuai, et al.
Publicado: (2020) -
The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule
por: Shen, Xuhui, et al.
Publicado: (2021)